SCHEMBL24088138

SCHEMBL24088138

N#Cc1c(SCC2=NCON2)[nH]c(=O)c(C#N)c1-c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 6/20 0.41
▸ NPSR1 Q6W5P4 5/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ PRNP P04156 5/20 0.41
▸ POLB P06746 2/20 0.41
▸ PKM P14618 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ SAE1 Q9UBE0 1/20 0.41
▸ UBA2 Q9UBT2 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ HPGD P15428 2/20 0.39
▸ PSMD14 O00487 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26847383 0.81 NPSR1 (0.42) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL26847372 0.78 SERPINH1 (0.43) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL24087933 0.77 NPSR1 (0.44) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL24087883 0.76 MEN1 (0.43) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL24087884 0.75 ACMSD (0.44) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL26847386 0.73 ACMSD (0.46) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL26847375 0.73 KDM4E (0.44) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL24087888 0.72 RXFP1 (0.50) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL23850227 0.72 ACMSD (0.68) RXFP1NPSR1MEN1KMT2APRNP
SCHEMBL26847377 0.71 RXFP1 (0.56) RXFP1NPSR1MEN1KMT2APRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S R L (IT) 2021-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 RXFP1 4311/4885NPSR1 2669/4885MEN1 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback